Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
Northcott J, Bartha G, Harris J, Li C, Navarro FCP, Pyke RM, Hong M, Zhang Q, Ma S, Chen TX, Lai J, Udar N, Saldivar JS, Ayash E, Anderson J, Li J, Cui T, Le T, Chow R, Velasco RJ, Mallo C, Santiago R, Bruce RC, Goodman LJ, Chen Y, Norton D, Chen RO, Lyle JM. Northcott J, et al. Among authors: bartha g. Oncotarget. 2024 Jun 20;15:407. doi: 10.18632/oncotarget.28581. Oncotarget. 2024. PMID: 38900651 Free article. No abstract available.
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Yarchoan M, et al. Among authors: bartha g. Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7. Nat Med. 2024. PMID: 38584166 Free PMC article. Clinical Trial.
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
Northcott J, Bartha G, Harris J, Li C, Navarro FCP, Pyke RM, Hong M, Zhang Q, Ma S, Chen TX, Lai J, Udar N, Saldivar JS, Ayash E, Anderson J, Li J, Cui T, Le T, Chow R, Velasco RJ, Mallo C, Santiago R, Bruce RC, Goodman LJ, Chen Y, Norton D, Chen RO, Lyle JM. Northcott J, et al. Among authors: bartha g. Oncotarget. 2024 Mar 14;15:200-218. doi: 10.18632/oncotarget.28565. Oncotarget. 2024. PMID: 38484152 Free PMC article.
Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay.
Saldivar JS, Harris J, Ayash E, Hong M, Tandon P, Sinha S, Hebron PM, Houghton EE, Thorne K, Goodman LJ, Li C, Marfatia TR, Anderson J, Morra M, Lyle J, Bartha G, Chen R. Saldivar JS, et al. Among authors: bartha g. Oncotarget. 2023 Aug 30;14:789-806. doi: 10.18632/oncotarget.28490. Oncotarget. 2023. PMID: 37646774 Free PMC article.
Withdrawal of 'Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation'.
Pyke RM, Mellacheruvu D, Dea S, Abbott CW, Zhang SV, Phillips NA, Harris J, Bartha G, Desai S, McClory R, West J, Snyder MP, Chen R, Boyle SM. Pyke RM, et al. Among authors: bartha g. Mol Cell Proteomics. 2023 Apr;22(4):100511. doi: 10.1016/j.mcpro.2023.100511. Epub 2023 Apr 3. Mol Cell Proteomics. 2023. Corrected and republished in: Mol Cell Proteomics. 2023 Apr;22(4):100506. doi: 10.1016/j.mcpro.2023.100506. PMID: 37019059 Free PMC article. Corrected and republished. No abstract available.
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms.
Abbott CW, Boyle SM, Pyke RM, McDaniel LD, Levy E, Navarro FCP, Mellacheruvu D, Zhang SV, Tan M, Santiago R, Rusan ZM, Milani P, Bartha G, Harris J, McClory R, Snyder MP, Jang S, Chen R. Abbott CW, et al. Among authors: bartha g. Clin Cancer Res. 2021 Aug 1;27(15):4265-4276. doi: 10.1158/1078-0432.CCR-20-4314. Clin Cancer Res. 2021. PMID: 34341053 Free PMC article.
Withdrawn: Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
Pyke RM, Mellacheruvu D, Dea S, Abbott CW, Zhang SV, Phillips NA, Harris J, Bartha G, Desai S, McClory R, West J, Snyder MP, Chen R, Boyle SM. Pyke RM, et al. Among authors: bartha g. Mol Cell Proteomics. 2021;20:100111. doi: 10.1016/j.mcpro.2021.100111. Epub 2021 Jun 12. Mol Cell Proteomics. 2021. Retraction in: Mol Cell Proteomics. 2023 Apr;22(4):100511. doi: 10.1016/j.mcpro.2023.100511. PMID: 34126241 Free PMC article. Retracted.
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC; Tumor Neoantigen Selection Alliance; Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Wells DK, et al. Cell. 2020 Oct 29;183(3):818-834.e13. doi: 10.1016/j.cell.2020.09.015. Epub 2020 Oct 9. Cell. 2020. PMID: 33038342 Free PMC article.
31 results